New Zealand markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0800-0.0100 (-0.92%)
At close: 04:00PM EDT

Context Therapeutics Inc.

2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
267 225 7416
https://www.contexttherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees9

Key executives

NameTitlePayExercisedYear born
Mr. Martin A. LehrCo-Founder, President, CEO & Director725.25kN/A1984
Ms. Jennifer Minai-AzaryCFO & Treasurer533.65kN/A1978
Mr. Alex C. Levit Esq.Chief Legal Officer & Corporate Secretary512.1kN/A1979
Mr. Christopher Beck M.B.A.Senior Vice President of OperationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Corporate governance

Context Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.